



PRELIMINARY INVESTIGATION OF THE MUCOADHESIVE PROPERTIES OF THERMALLY 
MODIFIED MUCIN ON METRONIDAZOLE TABLETS 
Original Article 
 
ERAGA SYLVESTER OKHUELEGBE*, ARHEWOH MATTHEW IKHUORIA, OKUNZUWA JULIUS IMUETINYAN, 
IWUAGWU MAGNUS AMARA 
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Benin, Benin City, 300001, Nigeria 
Email: eragaso@uniben.edu  
 Received: 06 Aug 2015 Revised and Accepted: 10 Sep 2015 
ABSTRACT 
Objective: To determine the effect of thermal treatment of mucin on the mucoadhesive and tablet parameters of metronidazole tablets. 
Methods: Mucin was extracted from the giant African snails (Archachatina maginata) by differential precipitation using acetone, air-dried and 
pulverized. Modification of the mucin powder was carried out using a regulated water bath at 60 and 100 °C and at varied times of 1 and 12 h and a 
micro-wave oven at varied wattage (100-600 W) and time. Ten batches of metronidazole tablets (A1-A10) were prepared with the modified mucin 
by direct compression. Their granules were evaluated for flow properties and the tablets for weight uniformity, crushing strength, friability, drug 
content and in vitro studies. Tablet mucoadhesion was determined using the mass flow rate method. 
Results: Granules of all the batches exhibited good flow characteristics with their angles of repose<30 °. Tablets formulated passed the weight 
variation test with hardness values above 4.0 kp and friability of 1.10-1.85 % while the content of active drug met official compendial requirements. 
Tablets of treated mucin at 60 °C for 1 and 12 h gave mucoadhesion values of 1.80 g/sec This value was higher than those of the unmodified mucin 
tablets which gave 0.70 g/sec. Tablets of micro-wave treated mucin gave mucoadhesion values of 1.0-1.30 g/sec, which were also higher than that of 
the unmodified mucin 
Conclusion: The study shows that modification of mucin at 60 °C for 1 and 12 h may be considered as the most promising among the batches tested 
as their tablets had improved mucoadhesive properties compared to the unmodified mucin.  
Keywords: Thermal treatment, Micro-wave, Mucin, Mucoadhesion, Tablets, Metronidazole. 
 
INTRODUCTION 
Mucins are the major macromolecular constituent of the mucous 
secretions that coat the oral cavity and the respiratory, 
gastrointestinal and urinogenital tract of animals and, in some 
amphibians, the skin. They are responsible for the viscoelastic 
properties of the secretions, providing protection for the exposed 
delicate epithelia surfaces from microbial and physical injuries. 
Secretory mucins are typically of very high molecular mass and have 
hundreds of O-linked saccharide constituting between 50-80 % of 
the molecule by weight [1-4]. 
Mucins are ubiquitous in many human tissues. They are also 
negatively charged. This makes mucin a good candidate for drug 
delivery as they can be conjugated to positively charged drug 
molecules and targeted to the respective tissue. Its biomaterial 
properties can readily be modified by the use of other cationic 
polymers such as chitosan. Apart from the modification of the 
biomaterials properties, cationic polymers help to stabilize mucin as 
it can readily degrade to its motifs [5]. 
It is highly biocompatible, non-toxic and easily biodegradable. Mucin 
is often used for modelling of mucoadhesive and bioadhesive 
systems [6]. Thus, the interpretation of various polymers at the 
mucin polymer interface at a temperature higher than the glass 
transition temperature is often used to explain the mechanism of 
mucoadhesion [7]. The molecular bridges which result between 
mucin-polymer interpretation account for the adhesive strength. 
Apart from these bridges, the electronic properties of mucin help in 
mucoadhesion. Mucin therefore has high potential as a 
pharmaceutical excipient if adequately harnessed [8]. 
The mucoadhesive property of mucin can be improved upon or 
modified by treatment with different agents such that the medicament 
incorporated will achieve controlled release. The choice of modifying 
mucin thermally is to potentially enhance its properties with the 
benefit of increasing the drug releasing profile in the gastrointestinal 
tract and hence improve administration and absorption. 
The objective of the study was to determine the effect of thermal 
modification on the bioadhesive properties of mucin and to evaluate 
some tableting parameters of metronidazole matrix tablets 
formulated with the modified mucin. 
MATERIALS AND METHODS 
Materials  
The materials used were procured from local suppliers without 
further purification. All the reagents used were of certified analytical 
grade. Metronidazole (Huang Gang Yinhe Aarti Pharmaceutical Co. 
Ltd, China), acetone, methanol, lactose, magnesium stearate and talc 
were products of BDH Chemicals, England. Terrestrial Snails 
(Archachatina marginata, family-Arionidae) were purchased from a 
local market in Benin City, Nigeria. 
Extraction of snail mucin 
Mucin was extracted from the giant African land snails Archachatina 
marginata using the method described by Adikwu, et al. [9]. The 
snail shells were cracked and their fleshy bodies removed from the 
shells with the aid of a metal rod. Excretory materials accompanying 
the bodies were removed. A total weight of 100 g of the snail bodies 
was subjected to washing by squeezing off the slime from the fleshy 
bodies repeatedly into a pool of 250 ml of water and decanted. This 
procedure was repeated 2 more times to give a total decanted pool 
of 1 litre. Mucin was precipitated out of the pooled washings using 2 
L of chilled acetone. The precipitate was filtered and lyophilized to 
give brownish flakes. The dried flakes were blended in an electric 
blender to give mucin powders. The powder was stored in an 
airtight container until use.  
Modification of mucin powder 
The modification of mucin was carried out by weighing 10 g of 
mucin powder into 9 porcelain dishes (A1-A9). Porcelain dish A1 
was placed in a thermo-regulated water bath operated at 60 °C for 1 
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h with the powders stirred at intervals for even distribution of heat. 
Dish A2 was subjected to the same treatment for 12 h. The 
procedure was repeated for dishes A3 and A4 at 100 °C.  
Dishes A5-A7 were subjected to micro waving at 600 W, 300 W, 100 
W respectively for 10 min while A8 and A9 were micro-waved at 
100 W for 30 and 60 min respectively. The treated recovered mucin 
powders were kept in airtight containers prior to use. A schematic 
diagram of the modification process is shown in fig. 1. 
Evaluation of the modified mucin powder 
Solubility profile 
The solubility of a 1 % w/v dispersion of the modified mucin 
powders was determined in distilled water, methanol and acetone at 
ambient temperature (28±2 °C). The dispersions were allowed to 
stand for 24 h before measurements were taken. 
pH determination  
A 1 %w/v dispersion of the modified mucin powder was prepared 
with distilled water and allowed to stand for 1 h with the container 
capped at room temperature. The pH of the resultant solution was 
determined in triplicates using a digital pH meter (HI 2215, Hanna 
Instruments, USA).  
Melting point 
Modified mucin powders were packed into a capillary tube 
sealed on one side and tapped on a hard surface for the powders 
to form a column at the bottom of the capillary tube. The tube 
was inserted into the heating block of a Gallenkamp melting 
point apparatus. The temperature of the heating block was 
raised from room temperature at 0.5 °C per min until the sample 
melts and the melting temperature was recorded. Triplicate 
determinations were carried out per batch. 
 
 
Fig. 1: Schematic diagram showing different stages of the thermal treatment 
 
Preparation of mucoadhesive matrix granules and tablets 
Various batches of the modified mucin granules and tablets were 
prepared by dry granulation using the formula in table 1. Ten (10) 
batches of metronidazole granules (A1-A9) and a control batch 
(A10) containing the unmodified mucin were prepared using lactose 
as diluent. The ingredients of each batch were weighed and passed 
through a 710 mm mesh screen (Endecotts, England) prior to 
mixing. Screened quantities of metronidazole, mucin powders and 
lactose were transferred into a mortar and mixed intimately with a 
pestle. Specific screened quantities of magnesium stearate and talc 
were added stepwise and mixed thoroughly. The powder blend was 
slugged using a heavy-duty tableting machine (Karl Kolh Technical 
Supplies, Germany) and the resulting tablets were broken up into 
granules with a mortar and pestle. The granules were evaluated for 
pre-compression parameters before compressing into tablets using 
a single punch tableting machine (Manesty Machines, UK) at a 
pressure of 40 arbitrary units (AU). One hundred tablets were 
prepared per batch. Tablets from the various batches were 
evaluated for post-compression parameters. 
 
Table 1: Formula for the preparation of metronidazole mucoadhesive matrix granules/tablets 
Ingredients Quantity/tablet (mg) Quantity/batch (g) 
Metronidazole 200 20 
Mucin 200 20 
Lactose 100 10 
Magnesium stearate 25 2.5 
Talc 25 2.5 
 
Evaluation of granules and tablets 
Bulk density 
A 30 g quantity of the granules was poured gently into a 100 ml 
graduated measuring cylinder. The volume of the granules was read 
and the bulk density calculated. 
Tapped density 
The measuring cylinder containing the 30 g of granules was tapped 
100 times on a wooden platform. The volume was noted and used in 
calculating the tapped density. Carr’s index and Hausner’s ratio were 
computed from the bulk and tapped density values obtained. 
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Angle of repose 
The hollow tube method was used. A short hollow tube of 3 cm in 
internal diameter sitting on a circular horizontal surface of the same 
diameter was filled with granules. The tube was withdrawn 
vertically and excess, granules allowed to fall off the edge of the 
circular horizontal surface. The height of the heap was measured. 
The angle of repose, θ, was calculated using Equation 1. 
θ = tan-1
The dissolution profiles of the metronidazole tablets were 
determined using the BP basket method for the various batches of 
the tablets (Caleva ST7, UK). A dissolution medium of 900 ml of SGF 
maintained at 37±1 °C with a basket revolution of 50 rpm was used. 
A 5 ml aliquot of the dissolution medium was withdrawn at various 
intervals and replaced with an equivalent volume maintained at the 
same temperature (37 ± 1 °C) of the dissolution medium. The 
samples were filtered and diluted with more volume of SGF. This 
was carried out for 60 min. The absorbances of the resulting 
solutions were measured at λmax of 275 nm. The concentration and 
the percentage of drug released at each time interval was 
determined using the equation from the standard calibration plot 
obtained for the pure drug. A minimum of triplicate determinations 
was carried out for all batches and the results were reported as 
mean±SD. 
 (h/r) -----1 
Where h is the height of the heap of granules and r is the radius of 
the circular base 
Tablet evaluations  
The following tests were carried out on the compressed tablets 
using standard procedures: tablet weight uniformity, friability, 
hardness test and dissolution rate [10]. 
Weight uniformity and friability 
The weight of each of 20 tablets was determined from each batch 
using an electronic balance (College B154, Mettler Toledo, 
Switzerland) and the mean weight and standard deviation were 
computed. Ten weighed tablets were then placed in the drum of a 
friabilator (Erweka GmbH, Germany) revolving at 25 rpm which 
exposed the tablets to rolling and repeated shock resulting from free 
fall within the apparatus. After 4 min, the tablets were brought out, 
dedusted and reweighed. The weight was then recorded and 
friability calculated as the percentage loss in weight. 
Tablets hardness  
The hardness of each of ten tablets per batch was determined 
(Campbell Electronics, Model HT-30/50, India). The mean hardness 
and standard deviation were calculated. 
Content of active drug 
Twenty (20) tablets were randomly selected from each batch and 
crushed to fine powder. A quantity of the powdered tablets 
equivalent to 200 mg metronidazole was weighed and dissolved in 
about 50 ml of simulated gastric fluid (SGF) in a 100 ml volumetric 
flask. The volume was made up with more SGF and allowed to 
hydrate for 5 h. Necessary dilutions were carried out to obtain a final 
concentration of 100 μg/ml. The solution was thereafter filtered 
through a Whatman No. 1 filter paper and the absorbance (T70, PG 
Instruments Ltd, USA) of the filtrate determined at 275 nm using 
SGF as blank. The amount of the drug was determined using the 
equation from the standard calibration plot obtained from pure 
metronidazole powder. 
Dissolution studies  
Bioadhesion test 
This test was carried out for each batch of tablets using the method 
of Attama et al. [11], with some modification. Freshly excised albino 
rabbit ileum of about 10 cm was pinned on the plastic support at an 
angle of 30 ° and a tablet was placed on the exposed hydrated mucus 
surface for a period of 5 min, to allow for tablet mucus interaction 
and hydration. A burette was then filled with simulated gastric fluid 
and then allowed to flow over the tablet using lamina flow rate of 2 
ml/sec until the tablet detaches from the excised ileum. The mass 
flow rate of SGF (g/sec) was then used as a measure of bioadhesion. 
The test was carried out in triplicates and the average values 
recorded. 
Release kinetics 
Data of in vitro release were fitted into different equations to 
determine the release kinetics of metronidazole from the 
mucoadhesive tablets. The kinetic equations used were zero order, 
first order, Higuchi and Korsemeyer-Peppas models to interpret the 
drug release mechanism from the tablets. 
Statistical analysis 
Data analysis was carried out using GraphPad InStat software 
version 3.10. Inferential statistical difference of the batches 
parameters was obtained using the student’s t-test at the 5 % level 
of significance. 
RESULTS AND DISCUSSION 
Physicochemical properties 
Results from the physicochemical tests on the modified mucin 
powders are shown in table 2. The solubility profiles at room 
temperature shows no solubility of all the batches in methanol, 
acetone and distilled water. There was partial solubility of batch 
A1 in methanol and acetone and the unmodified mucin A10 in 
distilled water. There were reductions in the melting points of the 
modified batches with reference to the unmodified mucin while all 
the modified sample powders were alkaline in pH. The 
implications of these results could be that the modification carried 
out did not affect much of the physical properties of mucin as 
there could have been a distortion of mucin tertiary or quaternary 
structure from the modification without any effect on its primary 
structure. 
 
Table 2: Some physicochemical parameters of the modified mucin powders 
Batch Solubility Melting 
point 
pH 
Methanol Acetone Water 
A1 + + - 85 7.68 
A2 - - - 86 7.56 
A3 - - - 86.5 7.60 
A4 - - - 80 7.57 
A5 - - - 81.5 7.40 
A6 - - - 83 7.45 
A7 - - - 84.5 8.45 
A8 - - - 86 8.20 
A9 - - - 87 7.90 
A10 - - + 89.5 8.30 
(-) Not soluble, (+) sparingly soluble 
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Flow properties of granules 
The flow parameters of the formulated granules are shown in table 
3. The results show comparable values among the batches of 
granules with no significant differences among them (p<0.05). The 
Carr’s indices, Hausner’s ratios and angles of repose suggest free 
flowing granules. 
Tablet characteristics  
The result of some of the physicochemical parameters of the 
bioadhesive tablets prepared for the various batches of the active 
drugs is shown in table 4. The British Pharmacopoeia [10] specifies 
that not more than two of the individual weight should deviate from 
the average weight of tablets by more than±5 % and none should 
deviate by more than±10 %. 
The mucoadhesive tablets of the different batches met this specification. 
All the batches of tablets had hardness values above 4 kp. Though this is 
an unofficial test, however a minimum hardness of 4 kp is desirable. This 
may be due to the fact that the concentration of the mucin was sufficient 
in binding the drug.  Friability values of 0.8-1 % are frequently quoted as 
the upper level of acceptance for pharmaceutical products. Though, in 
direct compression formulation, values of up to 2 % or above have been 
reported. The results listed in table 4 show that all the tablet batches 
partially conformed to specifications. The friability test can also be 
adopted for the measurement of granule strength [12]. It is unlikely that 
in the normal life of a tablet it will be subjected to a compressive load 
large enough to fracture it. However, it may well be subjected to 
tumbling motion, e. g., during coating, packaging or transportation, 
which whilst not severe enough to break the tablet, may abrade small 
particles from its surface [13].  
 
Table 3: Flow properties of formulated metronidazole bioadhesive granules 
Batch Bulk density (g/cm3 Tapped density (g/cm) 3 Carr’s index (%) ) Hausner ratio Angle of repose ( °) 
A1 0.6442±0.02 0.7100±0.03 9.3 1.1 28.30 
A2 0.6433±0.04 0.7095±0.09 9.3 1.1 31.21 
A3 0.6621±0.02 0.7122±0.06 7.0 1.1 28.32 
A4 0.6413±0.06 0.7099±0.04 9.7 1.1 30.02 
A5 0.6513±0.10 0.7202±0.05 9.6 1.1 30.02 
A6 0.6611±0.08 0.7213±0.08 8.3 1.1 29.01 
A7 0.6512±0.09 0.7124±0.10 9.0 1.1 27.11 
A8 0.6611±0.07 0.7193±0.11 8.1 1.1 29.14 
A9 0.6121±0.06 0.7163±0.04 9.7 1.2 29.11 
A10 0.6357±0.04 0.7026±0.02 9.52 1.2 29.17 
Values are mean±standard deviation (n=3). 
 
Table 4: Some physicochemical parameters of the different batches of tablets formulated 
Batch Weight uniformity (g) Hardness (kp) Friability (%) Drug content (%) 
n 20 10 10 20 
A1 0.51±0.04 4.86±0.42 1.34±0.003 99.5 
A2 0.52±0.03 4.48±0.54 1.42±0.007 98.8 
A3 0.53±0.02 4.55±0.30 1.43±0.008 101.4 
A4 0.52±0.02 4.94±0.59 1.20±0.007 98.4 
A5 0.52±0.03 4.92±0.59 1.26±0.003 100.2 
A6 0.52±0.02 4.94±0.59 1.36±0.008 98.6 
A7 0.52±0.03 4.00±0.97 1.32±0.007 100.2 
A8 0.52±0.20 4.43±0.39 1.85±0.009 97.5 
A9 0.54±0.20 4.28±0.49 1.25±0.007 98.0 
A10 0.52±0.02 4.56±0.31 1.10±0.012 99.5 
Values are mean±standard deviation 
 
Bioadhesion 
The results of bioadhesion of tablets (fig. 2) showed that the batches 
A1 and A2 tablets gave the highest bioadhesion; this was closely 
followed by A3. The A10 batch of tablets prepared with the 
unmodified mucin powders gave the least bioadhesive effect. There 
was a significant increase in the bioadhesion properties of the 
thermally modified mucin. The mucin modified using moist heat 
over a thermostated water bath produced tablets with greater 
bioadhesion properties than those prepared using micro-wave 
assisted modification. It is likely that the higher humidity of 
modification of batches A1-A3 led to irreversible softening and 
increased gelling tendency of the mucin powder. In the micro-wave 
assisted, dry heat was involved and the sudden exposure of the 
mucin powder to dry heat may have resulted in hardening of the 
powder particles hence achieving either a reduction or no significant 
effect on the bioadhesion property of the mucin powder despite the 
intensity or duration of heat applied. 
There was also no significant difference between the times of 
modification as the A1 and A2 batches gave similar bioadhesion 
properties since the desired levels of hydration and softening of the 
mucin polymer were achieved within 1 h. There would therefore be 
no need to heat for up to 12 h. 
 
 
Fig. 2: Bioadhesion of the different batches of thermal modified 
mucin. Data are expressed as the mean±SD (n= 3) 
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In vitro drug release 
In-vitro drug release studies revealed differences in the release of 
metronidazole from the different tablet formulations in SGF as 
shown in fig. 3a and b. There were variations in the drug release 
profile among the different batches of the tablets. There was some 
level retardation in the release of metronidazole from the matrix 
tablets in the first 10 min. However, these delays by the different 






Fig. 3a-b: Dissolution profile of the different batches of the 
metronidazole tablets in SGF. Data are expressed as the 
mean±SD (n= 3) 
 
The correlation coefficient (r2
Table 5: Correlation coefficient (r
) values of the metronidazole 
bioadhesive tablets are shown in table 5. The result indicates that 
the relationship between drug release and time is not linear in SGF, 




) of the dissolution studies 
Release kinetic 
Zero order First order Higuchi Korsemeyer-Peppas 
r2(n) 
A1 0.9510 0.9538 0.9699 0.9084 (11.240) 
A2 0.9547 0.9570 0.9666 0.9090 (12.150) 
A3 0.9589 0.9614 0.9221 0.9186 (14.366) 
A4 0.9778 0.9779 0.8043 0.8908 (16.443) 
A5 0.9556 0.9573 0.9386 0.9064 (14.211) 
A6 0.9765 0.9641 0.9363 0.9359 (13.319) 
A7 0.9157 0.8842 0.9635 0.9081 (10.976) 
A8 0.9757 0.9501 0.9180 0.9292 (13.787) 
A9 0.7646 0.7812 0.9518 0.9013 (03.934) 
A10 0.9320 0.9329 0.8914 0.9064 (16.835) 
 
CONCLUSION 
The study shows that modification of mucin at 60 °C for 1 and 12 h 
may be considered as the most promising among the batches tested 
with the highest mucoadhesion values. Inclusion of modified mucin 
in the batches also showed some promise in controlling drug release 
from the matrix tablet. Therefore matrix tablet made from these 
modifications will ensure optimum therapeutic level with minimum 
adverse effect and may find usefulness in mucoadhesive 
formulations of metronidazole for the gastrointestinal tract and 
vagina mucosa. 
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